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Voriconazole (VRC) is a second-generation triazole with a broad antimycotic spectrum including Aspergillus and non-albicans Candida species. It is the drug of choice for treatment of invasive aspergillosis (12, 27). The bioavailability after oral intake of VRC is reported to be almost complete (96%) in healthy volunteers, but lower and variable in patients (23.7 to 63.3%) (11). Since data on VRC distribution into human tissues have been sparse so far, we 5 determined concentrations in autopsy samples.
The study was approved by the local ethics committee. Consent was granted by the patients' relatives. Tissue samples were obtained during routine autopsy from eight patients, who had died at the medical ICU during VRC treatment. Patients' characteristics and data on VRC therapy are displayed in table 1, routine laboratory values in table 2. 10 VRC (Vfend®, Pfizer) had been administered for possible, probable or proven invasive aspergillosis intravenously (six patients) or as an oral suspension (two patients) at standard dose. Aliquots (~7g) were taken from lung, brain, liver, spleen, kidneys and myocardium and were stored at -80°C. After thawing, samples were homogenized (Ultraturrax T25®, Germany) and purified by C18 solid phase extraction. VRC was quantified using the high-15 performance liquid chromatography method by Khoschsorur et al. (14) , with some modifications using a Zorbax 300SB-C18 analytical column, UV detection (λ = 255 nm) and a mixture of sodium dihydrogen phosphate buffer-acetonitrile-methanol (35:45:20, v/v) as mobile phase. The detection limit was 0.25 µg/g. The intraday-, interday-precision, and accuracy (mean ± standard deviation) were 4.2 ± 3.7%, 8.8 ± 5.2% and 7.4 ± 9.6%, 20 respectively. The concentrations were assessed by means of a linear standard-curve (R=0.999), obtained by external standards comprising respective bovine tissues spiked with VRC. The mean VRC recovery was 80%. However, with our method we could not study the VRC distribution on a cellular level.
In pulmonary epithelial lining fluid (ELF) of lung transplant recipients, VRC levels were between 0.3 and 83.3 µg/ml (3). In ELF of healthy volunteers, mean levels amounted to 10.1 to 48.3 µg/ml, in alveolar macrophages 10.3 to 20.6 µg/ml (5). Thus, the mean VRC 5 concentration we found in lung tissue was somewhat lower than that in ELF. In-vitro incubation of polymorphonuclear leucocytes with 2 µg/ml of VRC resulted in intra-cellular levels of ~15 µg/ml (1). Relatively low amounts of VRC (0.7-4.4 µg/ml) were recovered from pleural fluid (17, 21, 23). VRC penetration into cerebrospinal fluid appears to be variable yielding levels of 0.08-3.93 µg/ml (7, 16). Cerebral VRC concentrations have been 10 determined previously in autopsy samples of two patients where 11.8 and 58.5 µg/g were measured and, thus, exceed the levels we measured in our study population (16). In a brain abscess 1.2-1.4 µg/g were reached by oral intake of 4 mg/kg twice daily (8) . In contrast, none of our patients presented with cerebral mycosis. Studies in chickens and horses revealed remarkable interspecies differences in tissue penetration of VRC (2, 4, 20). In rats free 15 extracellular lung concentrations reached ~2.5 µg/ml after a single dose (13).
Fluconazole, the ancestor drug of VRC, has been found to achieve high levels in various tissues including the brain (25) . In contrast, amphotericin B preparations accumulate in liver and spleen but achieve only low levels in brain and myocardium (26). Unlike with VRC, amphotericin B levels in lung tissue are much higher than in ELF (28). In comparison with 20 amphotericin B, VRC therapy of invasive aspergillosis achieved a superior clinical outcome (12). Echinocandins displayed a tissue distribution similar to that of amphotericin B in animal studies (9, 10, 24).
In conclusion, treatment with VRC at standard doses yields concentrations above MICs of relevant fungal pathogens in various frequently affected tissues. Legend to Tables:   TABLE 1 
